Atovaquone Proguanil and Artesunate Pyronaridine — Competitive Intelligence Brief

Atovaquone Proguanil and Artesunate Pyronaridine (Atovaquone Proguanil and Artesunate Pyronaridine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Plasmodium mitochondrial electron transport chain, dihydrofolate reductase, heme polymerase Infectious Disease Small molecule

Target snapshot

Atovaquone Proguanil and Artesunate Pyronaridine (Atovaquone Proguanil and Artesunate Pyronaridine) — Armed Forces Research Institute of Medical Sciences, Thailand. This combination drug uses atovaquone-proguanil to inhibit parasite mitochondrial function and pyronaridine-artesunate to generate reactive oxygen species and inhibit heme polymerization, together targeting multiple stages of malaria parasite development.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atovaquone Proguanil and Artesunate Pyronaridine TARGET	Atovaquone Proguanil and Artesunate Pyronaridine	Armed Forces Research Institute of Medical Sciences, Thailand	marketed	Antimalarial combination	Plasmodium mitochondrial electron transport chain, dihydrofolate reductase, heme polymerase
lumefantrine-artemether	lumefantrine-artemether	Centers for Disease Control and Prevention	marketed	Antimalarial combination	Malaria parasite (Plasmodium) hemoglobin metabolism and mitochondrial function
artesunate-amodiaquine (AS-AQ)	artesunate-amodiaquine (AS-AQ)	Yale University	marketed	Artemisinin derivative + aminoquinoline antimalarial combination	Plasmodium falciparum heme iron (Fe2+), parasite DNA, heme polymerase
Tafenoquine plus DHA-Piperaquine	Tafenoquine plus DHA-Piperaquine	Menzies School of Health Research	marketed	Antimalarial combination	Plasmodium hypnozoites (tafenoquine); Plasmodium blood-stage parasites (DHA-piperaquine)
Pyronaridine artesunate	Pyronaridine artesunate	Medicines for Malaria Venture	marketed	Antimalarial combination	Plasmodium falciparum DNA; heme detoxification pathway
Chloroquine + Primaquine	Chloroquine + Primaquine	U.S. Army Medical Research and Development Command	marketed	Antimalarial combination	Plasmodium parasite heme metabolism and mitochondrial function
lumefantrine plus artemether	lumefantrine plus artemether	Centers for Disease Control and Prevention	marketed	Antimalarial combination therapy	Malaria parasite heme metabolism and hemozoin formation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class